Tandutinib – 250 mg

Brand:
Cayman
CAS:
387867-13-2
Storage:
-20
UN-No:
Non-Hazardous - /

Tandutinib is a potent antagonist of platelet-derived growth factor receptor β (PDGFRβ), FLT3, and c-Kit (IC50 = 200, 220, and 170 nM, respectively).{24623} It less potently inhibits macrophage colony-stimulating factor 1 receptor (IC50 = 3.4 µM) and does not significantly inhibit other tyrosine or serine/threonine kinases.{24623,24622} Tandutinib blocks the growth of cells expressing an internal tandem duplication within the juxtamembrane domain of the FLT3 receptor, found in some acute myelogenous leukemia cells.{24623,24624} It also impairs the growth of colon cancer cells through its actions on the c-Kit receptor.{24621} Tandutinib reverses multidrug resistance in vitro by impairing the efflux activity of the multidrug resistance protein 7.{24625}  

 

Available on backorder

SKU: 12098 - 250 mg Category:

Description

A potent antagonist of the type III receptor tyrosine kinases PDGFRβ, FLT3, and c-Kit (IC50 = 200, 220, and 170 nM, respectively); less potently inhibits CSF-1R (IC50 = 3.4 µM) and does not significantly inhibit other tyrosine or serine/threonine kinases


Formal name: 4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-1-piperazinecarboxamide

Synonyms:  CT 53518|MLN518

Molecular weight: 562.7

CAS: 387867-13-2

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling||Research Area|Cancer|Multidrug Resistance